The FDA uses three distinct terms, and they are not interchangeable. A device is cleared through the 510(k) pathway when the FDA finds it substantially equivalent to a legally marketed predicate device. This is the route for most moderate risk, Class II devices, and it accounts for the vast majority of device submissions each year. A device is approved through Premarket Approval (PMA) when the FDA independently reviews clinical evidence and determines there is reasonable assurance of safety and effectiveness, a standard reserved for high risk Class III devices such as implantable heart valves. A device is granted marketing authorization through the De Novo pathway when it is novel, carries low to moderate risk, and has no suitable predicate to compare against.

The distinction matters beyond semantics. Payers, hospital value analysis committees, and journalists increasingly scrutinize how manufacturers describe their regulatory status, and imprecise language, calling a cleared device “FDA approved,” can create compliance exposure and credibility problems with sophisticated buyers.

Because the FDA answers one question: is the device reasonably safe and effective for its intended use. It does not evaluate whether the device fits an existing clinical workflow, whether a hospital has budget to acquire it, or whether an insurer will pay for the associated procedure. Those questions belong to different institutions entirely, operating on different evidence standards and different calendars.

Market access is the coordinated set of activities that gets an authorized device into actual clinical use: securing reimbursement, navigating procurement, building distribution, and generating the evidence that clinicians and health systems expect beyond what the FDA required. It sits at the intersection of regulatory affairs, health economics, commercial strategy, and clinical operations, and it typically starts well before authorization rather than after it.

Outside the United States, this discipline looks different by geography. In the European Union, CE marking under the Medical Device Regulation is followed by national reimbursement processes and formal health technology assessment. In the Gulf and much of Southeast Asia, market entry often requires separate national registration, local distribution partnerships, and procurement relationships with ministries of health, none of which follow automatically from a US or EU authorization.

Reimbursement in the US runs on three interdependent pillars: coding, which identifies the procedure or device for billing purposes; coverage, a payer’s decision to pay for it at all; and payment, the amount actually transferred. A missing or inadequate code can block payment even when a payer is otherwise willing to cover a technology.

The Centers for Medicare and Medicaid Services and private insurers evaluate new technologies on clinical and economic evidence that frequently differs from what the FDA required for authorization, and the gap between authorization and established reimbursement can run into years rather than months, a period some in the industry refer to as the valley of death. New CPT code applications commonly take 18 to 24 months, and manufacturers report typical timelines of two to five years to reach broad payer coverage. Building reimbursement strategy in parallel with regulatory strategy, rather than after authorization, reduces this gap.

Hospital and health system procurement runs through value analysis committees that weigh clinical benefit against total cost of ownership, training burden, and impact on existing supply chains. A device can be authorized and reimbursed and still lose to an incumbent because it disrupts a workflow the committee is not prepared to change.

Distribution determines whether a device physically reaches the point of care. In many international markets this means qualified local distributors with existing hospital relationships and regulatory registration capacity, not direct sales. Clinical adoption follows a similar logic. Physicians and care teams adopt new technology when it demonstrably improves outcomes or efficiency without requiring them to abandon proven technique, and that confidence is usually built through published clinical evidence, peer influence, and hands on training rather than a regulatory letter.

Positioning determines how a manufacturer frames its value to distinct audiences, clinical buyers, financial buyers, and payers, each of whom needs a different argument. Sales infrastructure, the commercial team, training programs, and channel relationships, has to exist and be resourced before authorization if a company wants to move quickly once it clears. Industry analysis of medtech startups points to a consistent pattern: a large share of ventures that fail to return capital to investors do so with clinically sound, regulatorily cleared products, undone by the absence of a market ready to receive them rather than by science.

Strategic partnerships, with distributors, health systems, or larger manufacturers, are often what closes that gap. They provide market access infrastructure a smaller company cannot build alone: existing procurement relationships, regulatory registrations in new geographies, and credibility with buyers who are cautious about unproven vendors.